Cellectar Biosciences Reports Positive Phase 2b Data for Iopofosine I 131 in Waldenström Macroglobulinemia and Secures $140M Financing for Phase 3 Trial and FDA Filing
Cellectar Biosciences Q1 2026 Financial Results & Corporate ...
Sign in to continue:
Cellectar Biosciences Q1 2026 Financial Results & Corporate ...
Legence Corp. Q1 2026 Financial Results: Key Details for Inv...
Hewlett Packard Enterprise Co (HPE) 8-K Report Analysis – Ma...
Genie Energy Reports First Quarter 2026 Results Genie ...
Incannex Healthcare Commences DReAMzz Clinical Study for IHL...
Karyopharm Therapeutics Q1 2026 Financial Results & Clinical...
enCore Energy Q1 2026 Financial Report – Detailed Investor A...
CorMedix Inc. Reports Exceptional Q1 2026 Results, Raises Fu...
Sunrise Realty Trust, Inc. Announces Q1 2026 Financial Resul...
Pyxis Oncology Q1 2026 Financial Results and Clinical Update...